The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice-Reference-Cited by-同舟云学术

The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice

Published:2021-05 Issue:5 Volume:47 Page:1191-1195
ISSN:0748-7983
Container-title:European Journal of Surgical Oncology
language:en
Short-container-title:European Journal of Surgical Oncology

Author:

Rutkowski Piotr^ORCID,Ziętek Marcin,Cybulska-Stopa Bożena,Streb Joanna,Głuszek Stanisław,Jankowski Michał,Łopacka-Szatan Karolina,Las-Jankowska Manuela,Hudziec Piotr,Klimczak Anna,Olesiński Tomasz,Świtaj Tomasz,Koseła-Paterczyk Hanna,Bylina Elżbieta,Osuch Czesław

Funder

Novartis

Pfizer

Publisher

Elsevier BV

Subject

Oncology,General Medicine,Surgery

Reference31 articles.

1. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up;Casali;Ann Oncol,2018

2. Combined therapy of gastrointestinal stromal tumors;Rutkowski;Surg Oncol Clin,2016

3. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection;Rutkowski;Cancer,2011

4. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis;Miettinen;Arch Pathol Lab Med,2006

5. Is the surgical margin in gastrointestinal stromal tumors different?;Rutkowski;Vis Med,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical importance of tumor rupture in gastrointestinal stromal tumor;Journal of Digestive Diseases;2023-06-17

2. Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features;La radiologia medica;2022-09-04

3. SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib;Gastric Cancer;2022-08-24

4. Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib;International Journal of Cancer;2022-06-30

5. Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients;Cancers;2022-06-08